Several studies have reported favorable outcomes of autologous hematopoietic stem cell transplantation (AHSCT) in highly active relapsing-remitting multiple sclerosis (MS; NEJM JW Neurol Feb 24 2015 and JAMA Neurol 2015; 72:159). However, comparisons to newer, highly effective agents are limited. In this study, investigators used the MSBase registry and propensity score matching to compare AHSCT to highly effective disease-modifying therapies. Of 4915 individuals included, 167 were treated with AHSCT, 2558 with fingolimod, 1490 with natalizumab, and 700 with ocrelizumab.
Among the subset of patients included in propensity-score matching, relapse reduction with AHSCT appeared superior to fingolimod (annualized relapse rate, 0.09 vs. 0.20) and…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)